{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"The Golden Triangle and the gaps: Rethinking UK biotech","slug":"the-golden-triangle-and-the-gaps-rethinking-uk-biotech","published_at":"2026-06-25T07:00:00+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/the-golden-triangle-and-the-gaps-rethinking-uk-biotech","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/3c9b72a356e85aaecbe0910a3bbebcf371e07ba918db3ae5816fc86bc34635ab/eyJlcGlzb2RlSWQiOiI0OGMyNzFkOC1kMTlmLTQ4ZjEtOGExNS1jNWQ0YzIxZGU5YTYiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEzYzRhNzAyZjc3NjM2MDE1OGVhNWQwL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTI0X18yMy0yMS01Mi5tcDMifQ==.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/3c9b72a356e85aaecbe0910a3bbebcf371e07ba918db3ae5816fc86bc34635ab/eyJlcGlzb2RlSWQiOiI0OGMyNzFkOC1kMTlmLTQ4ZjEtOGExNS1jNWQ0YzIxZGU5YTYiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEzYzRhNzAyZjc3NjM2MDE1OGVhNWQwL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTI0X18yMy0yMS01Mi5tcDMifQ==.mp3","summary":"In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing director at M Ventures and Maina Bhaman, partner at Sofinnova Partners. We explore the UK biotech ecosystem : from the Golden Triangle’s evolving role to the challenges of scaling companies, unlocking pension capital and staying globally competitive. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Hakan Goker , Managing Director, M Ventures Maina Bhaman , Partner, Sofinnova Partners Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.","meta_description":"In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing director at…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1177,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/the-golden-triangle-and-the-gaps-rethinking-uk-biotech/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/the-golden-triangle-and-the-gaps-rethinking-uk-biotech.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}